Fox Run Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Fox Run Management’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-27,804	Closed	-$1.15M	–	1068
2025 Q4	$1.15M	Buy	27,804 +14,241	+105%	+$571K	0.18%	155
2025 Q3	$527K	Sell	13,563 -22,180	-62%	-$721K	0.08%	475
2025 Q2	$989K	Buy	35,743 +24,391	+215%	+$621K	0.16%	196
2025 Q1	$252K	Buy	+11,352	New	+$234K	0.04%	731
2024 Q4	–	Sell	-9,723	Closed	-$243K	–	1030
2024 Q3	$243K	Buy	+9,723	New	+$237K	0.05%	617
2024 Q1	–	Sell	-12,546	Closed	-$220K	–	932
2023 Q4	$220K	Buy	+12,546	New	+$206K	0.06%	609
2023 Q2	–	Sell	-15,221	Closed	-$164K	–	828
2023 Q1	$164K	Buy	+15,221	New	+$201K	0.05%	561

Other funds holding KNSA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Fox Run Management's KNSA Position: Q1 2026 in Review

Fox Run Management sold out of Kiniksa Pharmaceuticals (KNSA) in Q1 2026, closing a stake of 27,804 shares — an estimated $1.15M sold.

Fox Run Management first reported a position in KNSA in Q1 2023 and held it in 7 quarters. The position peaked at $1.15M in Q4 2025. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.

Fox Run Management reported no remaining Kiniksa Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Fox Run Management sold 27,804 Kiniksa Pharmaceuticals shares in Q1 2026, an estimated $1.15M.
Fox Run Management first reported a position in Kiniksa Pharmaceuticals in Q1 2023 and held it in 7 quarters.
Fox Run Management's Kiniksa Pharmaceuticals position peaked at $1.15M in Q4 2025.
228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.

Based on Fox Run Management's 13F filing for Q1 2026, filed 12 May 2026.